NXL logo

NEXALIN TECHNOLOGY INC

NXLNASDAQ
🏆 #5221 by market capUS Equity
$1.68—
Last available close · quote unavailable
🔔
Track NXL
Get earnings, price moves & breaking news on Telegram
Track
24h—
7d▼ 21.0%
14d▼ 33.1%
30d▼ 68.1%
ytd▼ 90.0%
1y▼ 96.4%
🏦Market Cap
$2M
Small Cap
📈Revenue Growth (YoY)
24.2%
Healthy
📊Gross Margin
86.2%
High
💵FCF Margin
—
⚖️P/S Ratio
7.9x
Fair
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
—
52-Week Range
$1.59 – $49.50
Volume (shares)
—
Avg Volume (shares)
—
Shares Outstanding
830,000
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
$301,647
Last Q Revenue
$12,161
P/E Ratio
—
P/S Ratio
7.9x
EPS (TTM)
$-0.47
Dividend Yield
—
Dilution (1yr)
+102.1%
NXL logo

NEXALIN TECHNOLOGY INC

NXL
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$302K▲ +78.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
79.7%▲ +1.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$8M▲ +8.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$5M▲ +20.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
621K▲ +102.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$655K▲ +$80K YoY
StockOtter · stockotter.space

About NEXALIN TECHNOLOGY INC

Nexalin Technology, Inc. operates as a medical device firm specializing in the creation and advancement of neurostimulation therapies for mental health conditions in both the United States and China. The company commercializes its primary product, the Nexalin Device, which provides a non-invasive and drug-free treatment for anxiety and insomnia. This device functions by emitting a proprietary frequency-based waveform designed to elicit a beneficial response from mid-brain structures associated with various psychological disorders. Furthermore, Nexalin Technology is currently developing "Generation 2," a new medical device undergoing clinical trials. This future product aims to address a broader spectrum of health issues, including opiate addiction, persistent pain, Alzheimer's disease, and dementia. The company was founded in 2021 and has its headquarters in Houston, Texas.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.